Autoimmune Lymphoproliferative Syndrome Medication
- Author: Luke M Webb, MD; Chief Editor: Harumi Jyonouchi, MD more...
Agents used to treat autoimmune lymphoproliferative syndrome (ALPS) include immunosuppressants and immune globulins.
Initial therapy for autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP) includes corticosteroids. In refractory autoimmune cytopenias necessitating long-term steroid therapy, mycophenolate mofetil has been shown to be an effective steroid-sparing agent.
Prednisone is useful for treating inflammatory and allergic reactions; it may decrease inflammation by reversing increased capillary permeability and suppressing polymorphonuclear leukocyte (PMN) activity. It is the drug of choice for all adult patients with platelet counts below 50,000/µL. Asymptomatic patients with platelet counts higher than 20,000/µL or patients with counts of 30,000-50,000/µL with only minor purpura may not need therapy; withholding medical therapy may be appropriate for asymptomatic patients, regardless of platelet count.
Methylprednisolone decreases inflammation by suppressing migration of PMNs and reversing increased permeability. It is used as the alternative glucocorticoid of choice for all patients with severe life-threatening bleeding or children with platelet counts below 30,000/µL. Careful observation without medical treatment may be appropriate in some asymptomatic children.
Mycophenolate inhibits inosine monophosphate dehydrogenase (IMPDH) and suppresses de novo purine synthesis by lymphocytes, thereby inhibiting their proliferation. It inhibits antibody production. Two formulations are available; they are not interchangeable. The original formulation, mycophenolate mofetil (CellCept) is a prodrug that, once hydrolyzed in vivo, releases the active moiety, mycophenolic acid. A newer formulation, mycophenolic acid (Myfortic), is an enteric-coated product that delivers the active moiety.
Corticosteroids act as potent inhibitors of inflammation. They may cause profound and varied metabolic effects, particularly in relation to salt, water, and glucose tolerance, in addition to their modification of the immune response of the body. Alternative corticosteroids may be used in equivalent dosage. It is used in all patients with severe life-threatening bleeding or children with platelet counts below 30,000/µL. Careful observation without medical treatment may be appropriate in some asymptomatic children.
High-dose (1-2 g/kg IV) immune globulin may be considered for concomitant use with pulse-dose corticosteroids in those with severe AIHA.
Immune globulin intravenous is given as a temporary measure to increase platelets. It neutralize circulating myelin antibodies through anti-idiotypic antibodies; down-regulates proinflammatory cytokines, including interferon gamma; blocks Fc receptors on macrophages; suppresses inducer T and B cells while augmenting suppressor T cells; blocks the complement cascade; promotes remyelination; and may increase immunoglobulin G (IgG) in cerebrospinal fluid (10% of cases).
Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr. 1967 Jun. 70(6):891-9. [Medline].
Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995 Jun 16. 81(6):935-46. [Medline].
John MJ, Rajasekhar R, Mathews V. Autoimmune lymphoproliferative syndrome (ALPS): a rare cause of immune cytopenia. Indian Pediatr. 2008 Feb. 45(2):148-50. [Medline].
Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992 Mar 26. 356(6367):314-7. [Medline].
Sneller MC, Straus SE, Jaffe ES, Jaffe JS, Fleisher TA, Stetler-Stevenson M. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest. 1992 Aug. 90(2):334-41. [Medline]. [Full Text].
Holzelova E, Vonarbourg C, Stolzenberg MC, Arkwright PD, Selz F, Prieur AM. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med. 2004 Sep 30. 351(14):1409-18. [Medline].
Rao VK, Straus SE. Autoimmune Lymphoproliferative Syndrome. Young NS, Gerson SL, High KA. Clinical Hematology. 2006. Chapter 58.
Oliveira JB, Bidere N, Niemela JE, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 2007 May 22. 104(21):8953-8. [Medline].
Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010 Oct 7. 116(14):e35-40. [Medline]. [Full Text].
Rao VK, Straus SE. Causes and consequences of the autoimmune lymphoproliferative syndrome. Hematology. 2006 Feb. 11(1):15-23. [Medline].
Bristeau-Leprince A, Mateo V, Lim A, Magerus-Chatinet A, Solary E, Fischer A. Human TCR alpha/beta+ CD4-CD8- double-negative T cells in patients with autoimmune lymphoproliferative syndrome express restricted Vbeta TCR diversity and are clonally related to CD8+ T cells. J Immunol. 2008 Jul 1. 181(1):440-8. [Medline].
Fleisher TA. The autoimmune lymphoproliferative syndrome: an experiment of nature involving lymphocyte apoptosis. Immunol Res. 2008. 40(1):87-92. [Medline].
Oliveira JB, Fleisher TA. Autoimmune Lymphoproliferative Syndrome. Curr Opin All Clin Immunol. 2004. 4:497-503.
Ferrer R. Lymphadenopathy: differential diagnosis and evaluation. Am Fam Physician. 1998 Oct 15. 58(6):1313-20. [Medline].
Blessing J, Johnson J, Zhang K. Gene Reviews: Autoimmune Lymphoproliferative Syndrome. Gene Reviews. Available at http://www.ncbi.nlm.nih.gov/books/NBK1108/. Accessed: June 15, 2009.
Rao VK, Carrasquillo JA, Dale JK, Bacharach SL, Whatley M, Dugan F. Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS). Am J Hematol. 2006 Feb. 81(2):81-5. [Medline].
Rao VK, Dowdell KC, Dale JK, Dugan F, Pesnicak L, Bi LL. Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome. Am J Hematol. 2007 Dec. 82(12):1049-55. [Medline].
Turbyville J, Mikita C, Mudra K. Asplenia. Medscape Reference. Available at http://emedicine.medscape.com/article/885226-overview. Accessed: June 30, 3009.
Rao VK, Dugan F, Dale JK, Davis J, Tretler J, Hurley JK. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol. 2005 May. 129(4):534-8. [Medline].
Rao VK, Price S, Perkins K, Aldridge P, Tretler J, Davis J. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer. 2009 Jul. 52(7):847-52. [Medline]. [Full Text].
Teachey DT, Greiner R, Seif A, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009 Apr. 145(1):101-6. [Medline]. [Full Text].
Price S, Shaw PA, Seitz A, Joshi G, Davis J, Niemela JE, et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood. 2014 Mar 27. 123(13):1989-99. [Medline]. [Full Text].